Education
About Us
Working with TipRanks
Follow Us
Harmony Biosciences Holdings (HRMY)
NASDAQ:HRMY
Top Page
Harmony Biosciences Holdings
(NASDAQ:HRMY)
Select Model
Select Model
Rating:69Neutral
Price Target:
$29.00
▲(1.61% Upside)
Action:DowngradedDate:02/25/26
The score is supported by strong fundamentals (profitability and a strengthened, low-debt balance sheet) and a positive earnings-call outlook with reiterated blockbuster 2026 guidance and pipeline catalysts. It is held back primarily by very weak technicals (price far below key moving averages with negative MACD) and reduced confidence from the reported TTM zero operating/free cash flow figure.
Positive Factors
Revenue Growth & Commercial Execution
Consistent double-digit revenue growth and consecutive quarters of patient adds show durable commercial traction. With ~8,500 patients on therapy versus ~80,000 diagnosed, sustained refill persistence and physician adoption underpin a multi-quarter runway to hit the company’s reiterated $1.0–$1.04B 2026 WAKIX target.
Label Expansion & Pipeline Catalysts
Pediatric approval materially expands the label and addressable market while enabling potential pediatric exclusivity (additional 6 months). Coupled with five ongoing Phase III programs and several near-term readouts, the company has durable lifecycle-extension and new-indication pathways beyond the current adult narcolepsy franchise.
Balance Sheet Strength & Cash Generation
Robust 2025 operating cash flow and a large cash balance with minimal debt provide durable financial flexibility to fund multiple Phase III trials, commercial expansion, IP defense and potential M&A. Low leverage reduces refinancing risk and supports sustained investment through 2026 catalysts.
Negative Factors
Rising Operating Expenses and Margin Pressure
A sharp rise in R&D and commercial spend compresses near-term margins and reduces free cash flow unless revenue growth accelerates further. Elevated expense runway to support multiple Phase III programs means profitability metrics could remain pressured across several quarters, creating execution risk on margin recovery.
Single-Product Revenue Concentration
Revenue dependence on one approved product concentrates commercial and regulatory risk: generic entry, payer decisions or safety/regulatory setbacks would materially impact cash generation. Pipeline programs reduce but do not eliminate this concentration until additional approvals are realized, a multi-year process.
Residual IP/Litigation and Competitive Risks
An unresolved ANDA filer leaves meaningful uncertainty on exclusivity timing and potential generic erosion; pediatric exclusivity outcome is pivotal. Separately, multiple competitors in orexin-2 agonists and enrollment competition for registrational trials create durable development and market-share risks that can affect long-term franchise value.
Harmony Biosciences Holdings (HRMY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.65B
Dividend YieldN/A
Average Volume (3M)1.02M
Price to Earnings (P/E)13.6
Beta (1Y)1.06
Revenue Growth21.13%
EPS Growth50.86%
CountryUS
Employees268
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.38
Shares Outstanding57,840,614
10 Day Avg. Volume2,050,063
30 Day Avg. Volume1,021,435
Financial Highlights & Ratios
PEG Ratio1.74
Price to Book (P/B)2.47
Price to Sales (P/S)2.48
P/FCF Ratio6.18
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue1.30
Enterprise Value/Gross Profit1.69
Enterprise Value/Ebitda4.49
Forecast
1Y Price Target
$41.25Price Target Upside44.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)3.61
Revenue Forecast (FY)$1.01B
Harmony Biosciences Holdings Business Overview & Revenue Model
Company DescriptionHarmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
How the Company Makes MoneyHarmony Biosciences generates revenue primarily through the sale of its pharmaceutical products, particularly its marketed therapies for narcolepsy. The company earns money by selling its drugs through various distribution channels, including pharmacies and healthcare providers. Additionally, Harmony may engage in strategic partnerships with other pharmaceutical companies or healthcare organizations to enhance its product offerings, expand market reach, and facilitate research and development. The success of its revenue model is significantly influenced by the effectiveness of its therapies, the size of the target patient population, pricing strategies, and market access efforts.
Harmony Biosciences Holdings Earnings Call Summary
Earnings Call Date:Feb 24, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 05, 2026
Earnings Call Sentiment Positive
The call highlights strong commercial execution and clear momentum: record quarterly revenues (+21% YoY), robust cash generation ($348.2M) and a healthy cash balance ($882.5M); sustained patient adds and a reiterated blockbuster revenue guide for 2026 support a positive commercial outlook. The company is actively advancing a rich late-stage pipeline (5 Phase III programs) with multiple near-term catalysts (pitolisant GR NDA Q2 2026, pitolisant HD top line 2027, EPX-100 data H1 2027). Key challenges include a significant rise in operating expenses (~45% YoY), a near‑term drop in non-GAAP adjusted net income and EPS (~48% decline), ongoing ANDA litigation/IP uncertainty (one filer unresolved), and competitive/enrollment pressures in certain programs. Overall, achievements and forward-looking catalysts materially outweigh the risks, though litigation and elevated investment-driven expenses warrant monitoring.Q4-2025 Updates
Positive Updates
Record Quarterly and Annual Revenues
Q4 2025 net product revenue of $243.8M, up 21% year-over-year from $201.3M; full year 2025 WAKIX net product revenue of $868.5M, marking the highest quarterly and strong annual performance.
Sustained Patient Growth
Q4 marked the third consecutive quarter with approximately 400+ average patient adds (first time in franchise history), bringing WAKIX to ~8,500 average patients and supporting further growth opportunity within an estimated 80,000 diagnosed narcolepsy patients.
Blockbuster Guidance for 2026
Company reiterated guidance for WAKIX net revenue of $1.00B to $1.04B for 2026 (first time guiding to blockbuster status for the franchise).
Strong Cash Generation and Balance Sheet
Generated $348.2M of cash from operations in 2025 and ended Q4 with $882.5M in cash, cash equivalents and investments, providing capacity to fund pipeline advancement and BD opportunities.
Pipeline Advancements and Multiple Near-Term Catalysts
Five ongoing Phase III registrational trials across distinct CNS indications; pitolisant GR on track for NDA submission in Q2 2026 with target PDUFA Q1 2027; pitolisant HD top-line data expected in 2027 (PDUFA 2028); EPX-100 registrational programs enrolling with top-line data expected H1 2027 (PDUFA 2028); orexin-2 agonist BP1.15205 Phase I PK data expected mid-2026.
Label Expansion — Pediatric Cataplexy
FDA approval (Feb 13, 2026) of WAKIX for treatment of cataplexy in patients ≥6 years old, expanding indication to pediatric population and advancing path toward pediatric exclusivity (an additional 6 months regulatory exclusivity).
IP and ANDA Litigation Progress
Settled with 6 of 7 ANDA filers; based on settlements, potential generic entry would be no sooner than March 2030 if pediatric exclusivity is obtained (company states it is on track to obtain it); company confident in IP and will continue to defend it.
Clinical Efficacy Signals in Epilepsy Asset
EPX-100 label-extension/OLE data showed clinically meaningful seizure reductions (~50% median reduction and ~50% of patients with ≥50% reduction after ≥6 months exposure) with generally favorable tolerability and no new monitoring requirements.
Commercial Investments and Execution
Commercial organization expanding field-based teams by ~20% (field sales >10%, field reimbursement >50%, remote sales >10%) and launching process improvements including a new patient portal to shorten time to dispense and boost conversion.
Negative Updates
Decline in Non-GAAP Adjusted Net Income and EPS
Q4 non-GAAP adjusted net income was $33.4M or $0.57 per diluted share versus $64.2M or $1.10 in prior-year quarter — a decline of ~48% in adjusted net income and EPS year-over-year.
Sharp Increase in Operating Expenses
Total operating expenses in Q4 were $136.7M vs $91.1M in Q4 2024 — an increase of approximately 45%, driven by R&D investments, commercialization spend, and ANDA litigation/settlement costs.
Ongoing Litigation Uncertainty and Residual IP Risk
While 6 of 7 ANDA filers settled, one filer remains and a recent trial outcome is pending; timing of judge’s decision and potential appeals are uncertain. If pediatric exclusivity is not granted, generic entry could occur earlier (company notes Sept 2029 as possible without exclusivity).
Near-Term Enrollment and Competitive Pressures
Enrollment competition noted for pitolisant HD Phase III narcolepsy and IH studies; multiple companies active in the orexin-2 agonist space (e.g., Takeda ahead with NDA), which could affect development/timing and positioning.
Q1 Seasonal Headwinds
Company expects industry Q1 seasonality: higher gross-to-net deductions due to insurance resets, higher co-pay obligations, and potential trade inventory drawdown that may pressure Q1 2026 phasing of revenues.
Increased R&D Spend Planned
Guidance indicates significant increases in R&D investments in 2026 to support five (and potential sixth) ongoing registrational Phase III programs, implying continued elevated expense runway.
Company Guidance
Harmony reiterated blockbuster guidance for WAKIX net revenue in 2026 of $1.0 billion to $1.04 billion (after an earlier, broader comment of $1.0–$1.40B), building on Q4 net product revenue of $243.8M (up 21% from $201.3M YoY) and full‑year 2025 WAKIX revenue of $868.5M, with Q4 marking a third consecutive quarter of ~400+ average patient adds and ~8,500 average patients on therapy against an ~80,000 diagnosed narcolepsy population; the company finished Q4 with $882.5M cash and generated $348.2M operating cash in 2025, reported Q4 operating expenses of $136.7M (vs. $91.1M prior year) and non‑GAAP net income of $33.4M ($0.57/diluted share), expects higher R&D spend in 2026 to support five ongoing Phase III registrational trials (with a potential sixth), remains on track for pitolisant GR NDA in Q2 2026 (PDUFA target Q1 2027) and other pipeline readouts (e.g., TEMPO H2 2026, EPX‑100 top line H1 2027), anticipates typical Q1 seasonality (higher gross‑to‑net and inventory drawdown), and notes IP progress with settlements with 6 of 7 ANDA filers and generic entry no sooner than March 2030 if pediatric exclusivity is granted.Harmony Biosciences Holdings Financial Statement Overview
Summary
Income statement and balance sheet are strong (high profitability, solid growth, and very low debt), but the TTM cash flow print of zero operating/free cash flow materially reduces near-term cash-flow confidence despite historically good cash conversion.Income Statement
HRMY shows strong profitability and solid growth. Revenue rose meaningfully from 2021–2024 and is up ~5% in TTM (Trailing-Twelve-Months). Profitability is a key strength, with TTM gross margin around 78% and net margin around 22%, supporting healthy earnings power. The main weakness is margin compression versus prior peaks (notably 2022), as operating and EBITDA margins have trended down from earlier highs even while staying strong in absolute terms.86
Very Positive
Balance Sheet
The balance sheet has strengthened substantially over time, with leverage falling sharply and equity building. Total debt is very low in TTM (Trailing-Twelve-Months) versus the prior years, and debt relative to equity has improved from highly leveraged levels in 2020–2021 to a conservative profile. Returns on equity remain strong (about 25% in TTM), though they are below the unusually high 2022 level, implying profitability is still healthy but less outsized than at peak.90
Very Positive
Cash Flow
Cash generation quality looks strong in the annual periods, with operating cash flow consistently exceeding net income and free cash flow closely tracking earnings (2021–2024). However, TTM (Trailing-Twelve-Months) operating and free cash flow are reported as 0, alongside a -100% free cash flow growth figure, which creates a major near-term red flag and likely reflects a data anomaly or a sharp timing-driven swing. Until TTM cash flow normalizes, cash-flow visibility is weaker than income statement and balance sheet strength suggest.62
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 868.45M | 714.73M | 582.02M | 437.86M | 305.44M |
| Gross Profit | 670.11M | 557.92M | 460.79M | 354.37M | 249.92M |
| EBITDA | 255.05M | 233.41M | 221.51M | 146.87M | 80.46M |
| Net Income | 158.69M | 145.49M | 128.85M | 181.47M | 34.60M |
Balance Sheet | |||||
| Total Assets | 1.27B | 999.20M | 811.45M | 673.87M | 433.44M |
| Cash, Cash Equivalents and Short-Term Investments | 775.34M | 467.19M | 353.46M | 323.12M | 234.31M |
| Total Debt | 239.58M | 181.41M | 193.57M | 191.65M | 195.74M |
| Total Liabilities | 401.41M | 340.05M | 344.46M | 271.03M | 246.94M |
| Stockholders Equity | 870.22M | 659.15M | 466.99M | 402.84M | 186.51M |
Cash Flow | |||||
| Free Cash Flow | 347.89M | 218.67M | 219.07M | 144.29M | 98.26M |
| Operating Cash Flow | 348.20M | 219.82M | 219.39M | 144.47M | 98.56M |
| Investing Cash Flow | -39.65M | -67.48M | -46.44M | -141.83M | -100.30M |
| Financing Cash Flow | -9.05M | -11.00M | -105.55M | 6.84M | 7.42M |
Harmony Biosciences Holdings Technical Analysis
Negative
28.54
Price Trends
35.52
Negative
34.14
Negative
33.98
Negative
Market Momentum
-2.33
Positive
31.97
Neutral
28.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HRMY, the sentiment is Negative. The current price of 28.54 is below the 20-day moving average (MA) of 32.84, below the 50-day MA of 35.52, and below the 200-day MA of 33.98, indicating a bearish trend. The MACD of -2.33 indicates Positive momentum. The RSI at 31.97 is Neutral, neither overbought nor oversold. The STOCH value of 28.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HRMY.
Harmony Biosciences Holdings Risk Analysis
Harmony Biosciences Holdings disclosed 67 risk factors in its most recent earnings report. Harmony Biosciences Holdings reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Harmony Biosciences Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $1.65B | 13.56 | 20.75% | ― | 21.13% | 50.86% | |
63 Neutral | $2.99B | -228.91 | -9.30% | ― | 129.21% | 80.35% | |
53 Neutral | $1.71B | -19.61 | -9.59% | ― | 27.51% | 38.72% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.63B | -22.81 | -36.21% | ― | 58.12% | 24.08% | |
49 Neutral | $6.01B | -7.30 | -73.70% | ― | ― | 4.32% |
* Healthcare Sector Average
HRMY
Harmony Biosciences Holdings
28.54
-5.20
-15.41%
ARDX
Ardelyx
6.65
1.21
22.24%
COGT
Cogent Biosciences
37.02
29.35
382.66%
ARQT
Arcutis Biotherapeutics
24.12
9.34
63.19%
IMCR
Immunocore Holdings
33.73
3.48
11.50%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.